Lv1
42 积分 2024-01-08 加入
PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial
1天前
已完结
Recompensation of decompensated cirrhosis in hepatitis C patients after SVR: Prognostic implications
3天前
已完结
OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
5天前
已完结
Alcohol-Related Liver Disease Including New Developments
4个月前
已完结
The circulating proteomic signature of alcohol-associated liver disease
5个月前
已完结
Role and Mechanisms of Mitophagy in Liver Diseases
5个月前
已完结
Role of mitochondria in alcoholic liver disease
5个月前
已关闭
Inflammatory pathways in alcoholic steatohepatitis
5个月前
已完结
Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease
5个月前
已完结
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
9个月前
已完结
皖公网安备34019202002308
